3D Tissue Models

View Profile

Peer Reviewed Papers, Books, Chapters

Year Title Citation Authors Review type Summary Keywords File filename File mime type
1. 2009 Activation of mTORC1 signaling pathway in AIDS-related lymphomas (ARL). Am. J. Pathol., in press.
2. 2008 gc-signaling cytokines induce a regulatory T cell (Treg) phenotype in malignant CD4+ T lymphocytes. J Immunol, 181: 2506-2512
3. 2008 Malignant Tregs express low molecular splice forms of FOXP3 in Sézary syndrome Leukemia, 22: 2230-2239
4. 2008 Differential effects of interleukin(IL)-2 and IL-15 versus IL-21 on CD4+ cutaneous T-cell lymphoma cells. Cancer Res., 68:1083-1091
5. 2008 IL-2- and IL-15-induced activation of the rapamycin-sensitive mTORC1 pathway in malignant CD4+ T lymphocytes. Blood, 111: 2181-2189
6. 2008 AH Rook. IL-21 enhances antitumor responses without stimulating proliferation of malignant T-cells of patients with cutaneous T-cell Lymphoma. J Invest Derm, 128: 473-480
7. 2008 Oncogenic kinase NPM/ALK induces through STAT3 expression of immunosuppressive protein CD274 (PD-LI, B7-H1). Proc. Natl. Acad. Sci. USA, 105: 20852-20857
8. 2007 Stat5a is epigenetically silenced in the NPM/ALK-transformed T lymphocytes and acts in such cells as tumor suppressor by inhibiting expression of the NPM/ALK oncogene. Nature Med. Nature Med., 13:1341-1348
9. 2007 Oncogenic tyrosine kinase NPM/ALK induces activation of the rapamycin-sensitive mTOR signaling pathway Oncogene, 26:5606-5614
10. 2007 Non-malignant T cells stimulate growth of T-cell lymphoma cells in the presence of bacterial toxins. Blood, 109:3325-3332
11. 2007 Constitutive activation of mTOR signaling pathway in post-transplant lymphoproliferative disorders (PTLDs). Lab Invest, 87:29-39
12. 2007 PU.1 regulates transcription of SHP-1 in hematopoietic cells J Biol Chem, 282:6316-6323
13. 2007 Loss of SHP-1 tyrosine phosphatase expression correlates with the advanced stages of cutaneous T-cell lymphoma (CTCL). Human Path, 38:462-467
14. 2007 Oncogenic tyrosine kinase NPM/ALK induces activation of the MEK/ERK signaling pathway independently of c-Raf. Oncogene 26:813-21
15. 2006 PPARg promotes lymphocyte survival through its actions on cellular metabolic activities J. Immunol., 177: 3737-3745
16. 2006 Mantle cell lymphoma cells express predominantly Cyclin D1a isoform and are highly sensitive to selective inhibition of CDK4 kinase activity. Blood, 108: 1744-1750,
17. 2006 NPM/ALK oncoprotein induces T regulatory cell phenotype by activating STAT3. Proc. Natl. Acad. Sci. USA, 103: 9964-9969
18. 2006 Expression of constitutively nuclear cyclin D1 in murine lymphocytes induces B-cell lymphoma. Oncogene, 25: 998-1007
19. 2006 Multi-gene epigenetic silencing of tumor suppressor genes in T-cell lymphoma cells; delayed expression of the p16 protein upon reversal of the silencing Leuk. Res., 30: 303-312
20. 2006 STAT3 induces transcription of the DNA methyltransferase 1 (DNMT1) gene in malignant T-lymphocytes Blood, 108: 1058-1064
21. 2006 Expression and oncogenic role of Brk (PTK6/Sik) protein tyrosine kinase in lymphocytes Am. J. Pathol., 168: 1631-1641
22. 2006 STAT5-induced Id1 transcription inhibitor/MMP9 metalloprotease axis enhances invasiveness of the BCR/ABL-transformed leukemic cells. Cancer Res., 66: 4108-4116
23. 2005 Activation of mTOR in transformed B lymphocytes is nutrient-dependent but independent of Akt, MEK, IGF-I, and serum Cancer Res., 65: 7800-7808
24. 2005 Treatment of primary Epstein-Barr virus infection in patients with X-linked lymphoproliferative disease using B-cell directed therapy. Blood, 105:994-996
25. 2005 Constitutive SOCS-3 expression protects T-cell lymphoma against growth inhibition by IFNa Leukemia, 19: 209-213
26. 2005 Inhibition of ALK enzymatic activity in T-cell lymphoma cells induces apoptosis and suppresses proliferation and STAT3 phosphorylation independently of Jak3 Lab. Invest., 85: 1544-1554
27. 2003 Detection of protein tyrosine-kinase (PTK) gene expression pattern in normal and malignant T lymphocytes by combined PTK-specific PCR and parallel denaturing gradient gel electrophoresis (DGGE). J. Mol. Diagn., 5: 113-120
28. 2003 Immunosuppressive signal transduction inhibitor RAD suppresses growth of cells derived from posttransplant lymphoproliferative disorder at allograft protecting doses. Transplantation, 75: 1710-1717
29. 2002 Diminished expression of the type II receptor for TGFß in T cells from patients with Sezary Syndrome is not due to mutations in the receptor’s poly-A tract: limitations of RT-PCR in cDNA sequence analysis of homopolymeric base stretches Arch. Immunol. Ther. Exp., 50: 421- 429
30. 2002 Expression of SHP-1 phosphatase indicates post-germinal center cell derivation of the B-cell post-transplant lymphoproliferative disorders (PTLDs). Lab. Invest., 82: 1599-1606
31. 2002 Complementary functions of the anti-apoptotic protein A1 and serine/threonine kinase pim-1 in the BCR/ABL-mediated leukemogenesis Blood, 99: 4531-4539
32. 2002 SHP2 regulates IL-2 induced MAPK activation, but not Stat3 or Stat5 tyrosine phosphorylation, in cutaneous T cell lymphoma cells Cytokine, 20:141-147
33. 2002 Multilevel dysregulation of STAT3 activation in ALK+ T/null-cell lymphoma J. Immunol, 168: 466-474
34. 2001 Role of phosphatidylinositol 3-kinase-Akt pathway in nucleophosmin/anaplastic lymphoma kinase-mediated lymphomagenesis Cancer Res., 61: 2194-2199
35. 2001 Role of signal transducer and activator of transcription 5 in nucleophosmin/ anaplastic lymphoma kinase-mediated malignant transformation of lymphoid cells Cancer Res 61: 6517-6523
36. 2001 Constitutive STAT3-activation in Sezary Syndrome (SS): tyrphostin AG490 inhibits STAT3- activation, interleukin-2 receptor expression and growth of leukemic Sezary cells Leukemia, 15: 787-793
37. 2001 Comparative genome-scale analysis of gene expression in T-cell lymphoma during malignant progression using a complementary DNA microarray. Am. J. Path., 158: 1231-1237
38. 2001 STAT3-mediated constitutive expression of SOCS-3 in cutaneous T-cell lymphoma Blood, 97: 1056-1061
39. 2000 Immunosuppressive macrolide SDZ RAD inhibits growth of human EBV-transformed B lymphocytes in vitro and in vivo; a potential approach to prevention and treatment of posttransplant lymphoproliferative disorders (PTLDs). Proc. Natl. Acad. Sci. USA, 97: 4285-4290
40. 2000 Bcl 2 expression restores the leukemogenic potential of a BCR/ABL mutant defective in transformation Blood, 96: 3915-3921
41. 2000 Lack of phosphotyrosine phosphatase SHP-1 expression in malignant T-cell lymphoma cells results from methylation of the SHP-1 promoter. Am. J. Path., 157: 1137-1146
42. 1999 Signal transducer and Activator of Transcription (STAT)5 activation by BCR/ABL is dependent on intact src homology (SH3) and SH2 domains of BCR/ABL and is required for leukemogenesis. J. Exp. Med., 189; 1229-1242
43. 1998 BCR/ABL SH3-mediated leukemogenesis requires activity of the small GTP-binding protein Rac. Proc. Natl. Acad. Sci. USA, 95: 11858-11862
44. 1998 Use of serum soluble interleukin-2 receptor levels to monitor patients with cutaneous T cell lymphoma treated with extracorporeal photophoresis J. Am. Acad. Dermatol., 38: 207-220
45. 1996 Blastic transformation of p53-deficient bone marrow cells by p210BCR/ABL tyrosine kinase. Proc. Natl. Acad. Sci. USA, 93: 13137-13142
46. 1996 Activation of Jak/STAT proteins involved in signal transduction pathway mediated by receptor for interleukin 2 in malignant T lymphocytes derived from cutaneous anaplastic large T-cell lymphoma and Sezary syndrome. Proc. Natl. Acad. Sci. USA, 93: 9148-9153

About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.